U.S. markets closed
  • S&P 500

    4,185.47
    +15.05 (+0.36%)
     
  • Dow 30

    34,200.67
    +164.68 (+0.48%)
     
  • Nasdaq

    14,052.34
    +13.58 (+0.10%)
     
  • Russell 2000

    2,262.67
    +5.60 (+0.25%)
     
  • Crude Oil

    63.07
    -0.39 (-0.61%)
     
  • Gold

    1,777.30
    +10.50 (+0.59%)
     
  • Silver

    26.04
    +0.08 (+0.29%)
     
  • EUR/USD

    1.1980
    +0.0004 (+0.04%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • GBP/USD

    1.3840
    +0.0056 (+0.41%)
     
  • USD/JPY

    108.7830
    +0.0670 (+0.06%)
     
  • BTC-USD

    55,026.02
    -6,006.66 (-9.84%)
     
  • CMC Crypto 200

    1,398.97
    +7.26 (+0.52%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.68 (+0.14%)
     

Portnoy Law: Lawsuit Filed On Behalf of Minerva Neurosciences, Inc. Investors

  • Oops!
    Something went wrong.
    Please try again later.
Portnoy Law
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Click here to join the case

LOS ANGELES, Feb. 02, 2021 (GLOBE NEWSWIRE) --

The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of Minerva Neurosciences, Inc. ("Minerva" or "the Company") (NASDAQ: NERV) investors that acquired securities between May 15, 2017 and November 30, 2020.

Investors are encouraged to contact attorney Lesley F. Portnoy, to determine eligibility to participate in this action, by phone 310-692-8883 or email, or click here to join the case.

It is alleged in the complaint that Minerva made misleading and false statements to the market. After its “end-of-Phase 2” meeting, Minerva failed to inform investors of the FDA’s true feedback. Minerva’s Phase 2b study failed to use the commercial formulation of roluperidone and was conducted exclusively outside of the United States. Due to failing to meet its primary and key secondary endpoints, Minerva’s Phase 3 study was rendered incapable of proving the drug’s effectiveness. The combination of the Phase 2b and Phase 3 trials would be “highly unlikely” to support an NDA submitted to the FDA. Throughout the class period, Minerva’s public statements were materially misleading and false, based on these facts. Investors suffered damages when the market learned the truth about Minerva.

Please visit our website to review more information and submit your transaction information.

The Portnoy Law Firm represents investors in pursuing claims arising from corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
lesley@portnoylaw.com
310-692-8883
www.portnoylaw.com

Attorney Advertising